DurgicalDurgical
EN
Open the app

Overactive bladder agents !

Medicines that calm an overactive bladder: antimuscarinics block detrusor contraction and beta-3 agonists relax it during filling.

Updated 2026-11-01

What they are

Overactive bladder is urgency, usually with frequency, night-time voiding and sometimes urge incontinence. Two drug groups are used: antimuscarinics (oxybutynin, tolterodine, solifenacin, darifenacin, fesoterodine, trospium) and beta-3 adrenergic agonists (mirabegron, vibegron).

Mechanism of action

Acetylcholine from parasympathetic nerves contracts the detrusor through M3 (and M2) receptors. Antimuscarinics block these receptors, lowering bladder pressure, raising capacity and reducing urgent contractions. Mirabegron stimulates beta-3 adrenergic receptors on the detrusor, relaxing it during the storage phase and increasing capacity without anticholinergic effects.

Target: Muscarinic M3 receptor (antimuscarinics); beta-3 adrenergic receptor (mirabegron)

Drugs in this class

Others in the class

  • Trospium (quaternary, cleared by the kidney)
  • Darifenacin
  • Fesoterodine (prodrug of the active tolterodine metabolite)
  • Vibegron (beta-3 agonist)

Test yourself

Think of the answer, then tap the question to see it.

Which three conditions contraindicate antimuscarinics for overactive bladder?

Urinary retention, gastric retention and uncontrolled narrow-angle glaucoma.

Which overactive bladder drug works through beta-3 receptors rather than muscarinic ones?

Mirabegron.

What is the most common reason for stopping an antimuscarinic?

Dry mouth.

Add to my cards (3)

← All of pharmacology

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., ch. 11 (McGraw Hill, 2023); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026); DailyMed - MIRABEGRON tablet, film coated, extended release (DailyMed (U.S. National Library of Medicine), 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.